These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol. Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450 [TBL] [Abstract][Full Text] [Related]
4. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. Tonry C; Russell-Hallinan A; McCune C; Collier P; Harbinson M; Dixon L; Watson CJ Cardiovasc Res; 2023 May; 119(3):710-728. PubMed ID: 35640873 [TBL] [Abstract][Full Text] [Related]
5. Role of biomarkers in chemotherapy-induced cardiotoxicity. Cardinale D; Sandri MT Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699 [TBL] [Abstract][Full Text] [Related]
6. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034 [TBL] [Abstract][Full Text] [Related]
7. Cardio-oncology: Clinical and imaging perspectives for optimal cardiodetection and cardioprotection in patients with cancer. Thuny F; Huttin O; Ederhy S Arch Cardiovasc Dis; 2019 Oct; 112(10):550-558. PubMed ID: 31522992 [No Abstract] [Full Text] [Related]
8. The Role of Biomarkers in Cardio-Oncology. Ananthan K; Lyon AR J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841 [TBL] [Abstract][Full Text] [Related]
9. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977 [TBL] [Abstract][Full Text] [Related]
10. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial. Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527 [TBL] [Abstract][Full Text] [Related]
11. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442 [TBL] [Abstract][Full Text] [Related]
12. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial. Díaz-Balboa E; Peña-Gil C; Rodríguez-Romero B; Cuesta-Vargas AI; Lado-Baleato O; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; González-Juanatey JR; González-Salvado V Prog Cardiovasc Dis; 2024; 85():74-81. PubMed ID: 38395212 [TBL] [Abstract][Full Text] [Related]
13. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736 [TBL] [Abstract][Full Text] [Related]
14. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Cardinale D; Biasillo G; Salvatici M; Sandri MT; Cipolla CM Expert Rev Mol Diagn; 2017 Mar; 17(3):245-256. PubMed ID: 28092472 [TBL] [Abstract][Full Text] [Related]
15. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937 [TBL] [Abstract][Full Text] [Related]
16. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050 [TBL] [Abstract][Full Text] [Related]
17. Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. Biersmith MA; Tong MS; Guha A; Simonetti OP; Addison D J Am Heart Assoc; 2020 Jan; 9(2):e013755. PubMed ID: 31960741 [No Abstract] [Full Text] [Related]
18. Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. Tromp J; Steggink LC; Van Veldhuisen DJ; Gietema JA; van der Meer P Clin Pharmacol Ther; 2017 Apr; 101(4):481-490. PubMed ID: 28073142 [No Abstract] [Full Text] [Related]
19. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Henriksen PA Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634 [TBL] [Abstract][Full Text] [Related]